Industry

With Patent Expiration Looming, HLB Seeks 'Combination Therapy Partners' for Rivoceranib in Korea

최영찬 기자 ·2025-12-16 10:56

This article was automatically translated by AI. There may be errors compared to the original Korean article. Read original in Korean →

[비즈한국] HLB028300 has begun revising its strategy to protect 'Rivoceranib,' the core pipeline responsible for most of the group's corporate value. Amid the dual pressures of delayed U.S. approval and approaching patent expiration, the company is attracting attention by moving away from its previous reliance on Chinese partners for combination therapy development and seeking a breakthrough in new combination strategies and patent extensions through collaborations with domestic biotech firms.

HLB is expanding collaborations with domestic companies as part of a patent extension strategy for the targeted anticancer drug Rivoceranib, which is facing patent expiration. Photo = Reporter Choi Young-chan

This article was automatically translated by AI. There may be errors compared to the original Korean article.

최영찬 기자

제약바이오 분야 출입하고 있습니다. 많이 듣고 많이 공부해 정확하게 쓰도록 하겠습니다.

chan111@bizhankook.com